Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis

Abstract

TNF inhibitors have the potential risk of ILD events, particularly for patients with pre-existing ILD, and KL-6 is a valuable surrogate marker for detecting ILD events. Our data suggest that non-TNF inhibitors are a better treatment option for these patients.